First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL.
Kim TW, et al. Among authors: siu ll.
Clin Cancer Res. 2022 Aug 15;28(16):3452-3463. doi: 10.1158/1078-0432.CCR-21-4020.
Clin Cancer Res. 2022.
PMID: 35699599
Free PMC article.
Clinical Trial.